Drug Profile
Melatonin oral gel - Spherium Biomed
Alternative Names: JAN-13004; Mucomel®; SP-13004Latest Information Update: 13 Jan 2022
Price :
$50
*
At a glance
- Originator Universidad de Granada
- Developer Spherium Biomed
- Class Anti-inflammatories; Chemoprotectants; Hormones; Radioprotectives; Sleep disorder therapies; Tryptamines
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Stomatitis
Most Recent Events
- 05 Sep 2018 Melatonin oral gel is still in phase I/II trials for Stomatitis (NCT02630004)
- 01 Jun 2018 Efficacy and adverse events data from the phase I/II MUCOMEL trial in stomatitis (Chemoradiation therapy induced oral mucositis) presented at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO-2018)
- 22 Dec 2017 Spherium Biomed completes a phase I/II trial in Stomatitis (Chemotherapy-induced) in Spain (PO) (EudraCT2015-001534-13) (NCT02630004)